NewLink Genetics Corp. (NASDAQ:NLNK) was up 3.1% during mid-day trading on Friday . The company traded as high as $11.26 and last traded at $11.23, with a volume of 98,382 shares changing hands. The stock had previously closed at $10.89.

A number of equities research analysts recently issued reports on NLNK shares. Stifel Nicolaus lowered their target price on shares of NewLink Genetics Corp. from $63.00 to $23.00 and set a “buy” rating for the company in a report on Tuesday, May 10th. Mizuho lowered their target price on shares of NewLink Genetics Corp. from $52.00 to $20.00 and set a “buy” rating for the company in a report on Tuesday, May 10th. Cantor Fitzgerald restated a “buy” rating and issued a $62.00 target price on shares of NewLink Genetics Corp. in a report on Friday, April 29th. Zacks Investment Research downgraded shares of NewLink Genetics Corp. from a “buy” rating to a “hold” rating in a report on Wednesday, July 13th. Finally, SunTrust Banks Inc. downgraded shares of NewLink Genetics Corp. from a “buy” rating to a “neutral” rating and lowered their target price for the company from $59.00 to $12.00 in a report on Tuesday, May 10th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and four have assigned a buy rating to the company’s stock. NewLink Genetics Corp. has an average rating of “Hold” and a consensus price target of $23.29.

The stock’s market capitalization is $318.34 million. The firm’s 50-day moving average is $11.06 and its 200 day moving average is $17.18.

NewLink Genetics Corp. (NASDAQ:NLNK) last posted its quarterly earnings data on Friday, April 29th. The company reported ($0.82) EPS for the quarter, beating analysts’ consensus estimates of ($1.70) by $0.88. The firm had revenue of $4.34 million for the quarter, compared to analysts’ expectations of $2.08 million. Analysts anticipate that NewLink Genetics Corp. will post ($2.62) EPS for the current fiscal year.

A number of hedge funds have recently bought and sold shares of NLNK. EQIS Capital Management raised its stake in NewLink Genetics Corp. by 587.5% in the fourth quarter. EQIS Capital Management now owns 41,644 shares of the company’s stock worth $1,515,000 after buying an additional 35,587 shares in the last quarter. Cornerstone Capital Management Holdings LLC. raised its stake in NewLink Genetics Corp. by 134.1% in the fourth quarter. Cornerstone Capital Management Holdings LLC. now owns 54,775 shares of the company’s stock worth $1,993,000 after buying an additional 31,375 shares in the last quarter. GSA Capital Partners LLP raised its stake in NewLink Genetics Corp. by 5.6% in the fourth quarter. GSA Capital Partners LLP now owns 65,571 shares of the company’s stock worth $2,386,000 after buying an additional 3,498 shares in the last quarter. California State Teachers Retirement System raised its stake in NewLink Genetics Corp. by 1.7% in the fourth quarter. California State Teachers Retirement System now owns 38,523 shares of the company’s stock worth $1,402,000 after buying an additional 636 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its stake in NewLink Genetics Corp. by 0.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 48,507 shares of the company’s stock worth $1,765,000 after buying an additional 300 shares in the last quarter.

NewLink Genetics Corporation is a biopharmaceutical company focused on discovering, developing and commercializing immunotherapeutic products for cancer treatment. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications. Its biologic product candidates are based on its HyperAcute immunotherapy technology platform, which is designed to stimulate the human immune system.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.